Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 07

15P - TIGIT+ CD8+ T cells limit the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer via NECTIN2-TIGIT interplay

Date

14 Sep 2024

Session

Poster session 07

Topics

Cancer Biology;  Tumour Immunology;  Translational Research

Tumour Site

Colon and Rectal Cancer

Presenters

Zhehui Zhu

Citation

Annals of Oncology (2024) 35 (suppl_2): S215-S228. 10.1016/annonc/annonc1574

Authors

Z. Zhu, W. Tang, Y. Lv, Y. Xu, P. Zhou, L. Ye, J. Xu

Author affiliations

  • General Surgery Department, Zhongshan Hospital Affiliated to Fudan University, 200032 - Shanghai/CN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 15P

Background

PD-1/PD-L1 blockade combined with chemoradiotherapy putatively benefited patients with dMMR/MSI-H colorectal cancer. However, the effect of PD-L1 blockade plus chemoradiotherapy for pMMR/MSS rectal cancer remains unclear, and the mechanisms influencing therapeutic response need further exploration.

Methods

A phase II, open-labeled, study was conducted to evaluate the efficacy and safety of adding Atezolizumab (PD-L1 blockade) to neoadjuvant chemoradiotherapy in MSS locally advanced rectal cancer (LARC). All patients received long-course radiotherapy plus capecitabine followed by three 21-day cycles Atezolizumab and TME surgery. Single cell RNA sequencing was performed on surgical resection samples.

Results

Twelve patients were recruited with 100% R0 resection. 50% (n=6) of MPR rate was observed, 3 of these patients achieved pCR. Interestingly, the proportion of T cells in the non-MPR group was significantly higher than in the MPR group, particularly TIGIT+ CD8+ T cells. However, further analysis indicated that the T cells in the non-MPR group were functionally exhausted. Compared to the MPR group, the interaction between NECTIN2+ cancer-associated fibroblasts and TIGIT+ CD8+ T cells was significantly enhanced in the non-MPR group. Mechanistically, the NECTIN2-TIGIT interaction limit the cytotoxic response by CD8+ T cells through inhibition of cyclic GMP-AMP synthase (cGAS)-STING pathway. Moreover, addition of TIGIT blockade to PD-L1 blockade plus chemoradiotherapy significantly enhances the therapeutic efficacy in MSS rectal cancer in vitro and in vivo.

Conclusions

NECTIN2-TIGIT serves as a crucial immune checkpoint for the efficacy of PD-L1 blockade plus chemoradiotherapy in MSS locally advanced rectal cancer, and the supplementary application of TIGIT blockade presents a rational approach for an immunotherapeutic combination strategy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

J. Xu.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.